Chemical Structure (Nayzilam 01)
Nayzilam Spray
Product Images NDC 50474-500
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Nayzilam (NDC 50474-500). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Nayzilam 02)
This appears to be a chart or graph of probabilities of having no seizures based on different treatment options after administration of a first double-blinded study dose over a certain span of hours. However, the text is not entirely clear and understandable without more context, and some characters are not readable, so a more accurate description cannot be provided.*
Figure (Nayzilam 03)
Figure 1 (Nayzilam 04)
Figure 2 (Nayzilam 05)
Figure 3 (Nayzilam 06)
Figure 4 (Nayzilam 07)
Figure (Nayzilam 08)
Principal Display Panel (5 mg Vial Blister Pack Carton)
Nayzilam (midazolam) nasal spray is a medication for nasal use only. Each carton contains 2 nasal spray units, with 1 dose per unit, each dose containing 5mg of midazolam in 0. mL of spray. The pharmacist should dispense the enclosed medication guide to each patient and the entire carton is to be dispensed. It is important not to test or prime before use, and not to use if the nasal spray unit appears damaged. The usual dosage and full prescribing information can be found in the package insert. The medication should be stored at a controlled room temperature of 20°C to 25°C (65°F to 77°F), with excursions permitted from 0°C to 15°C to 30°C (59°F to 86°F).*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
